Formononetin derivative containing benzyl piperidine as well as preparation method and application of formononetin derivative

By synthesizing benzylpiperidine-containing cyperidin derivatives, the problem of pesticide resistance and environmental impact on yeast bacteria is solved, and an effective inhibitor on yeast bacteria is provided, with low toxicity and environmental compatibility. sex.

CN119060026AActive Publication Date: 2024-12-03GUIZHOU UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411175187.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

Existing pesticides are resistant to plant pathogens such as flavonoidus, and have negative impacts on the environment and human health. They lack novel antibacterial agents that are low in toxicity, environmentally compatible and have unique mechanisms of action.

Method used

A series of compounds with inhibition of plant pathogenic bacteria were prepared by synthesizing benzylpiperidine-containing derivatives, especially for Xanthomonas.

Benefits of technology

Effectively inhibiting Xanthomonas and other plant pathogens, it provides a low-toxic and environmentally friendly alternative to antibacterial agents, which is significantly better than traditional pesticides in certain inhibitory activities.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005010531450000031
    Figure BDA0005010531450000031
  • Figure BDA0005010531450000061
    Figure BDA0005010531450000061
  • Figure BDA0005010531450000062
    Figure BDA0005010531450000062
Patent Text Reader

Abstract

The invention discloses a formononetin derivative containing benzyl piperidine as well as a preparation method and application of the formononetin derivative, and belongs to the technical field of pesticide synthesis. A benzyl piperidine group with excellent activity is introduced into the structure of formononetin, a series of formononetin derivatives containing benzyl piperidine are synthesized, and the activity of the synthesized formononetin derivatives containing benzyl piperidine in inhibiting plant pathogenic bacteria is tested. It is found that the formononetin derivative containing benzyl piperidine synthesized by the invention can effectively inhibit plant pathogenic bacteria, especially xanthomonas.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pesticide synthesis, and particularly relates to a formononetin derivative containing benzylpiperidine, and a preparation method and application thereof. Background Art

[0002] Bacterial plant diseases cause serious reductions in crop yield and quality. It is reported that bacteria of the genus Xanthomonas cause more than 350 different plant diseases. Notorious ones include: rice bacterial blight caused by Xanthomonas oryzae, citrus canker caused by Xanthomonas citri, mango angular leaf spot caused by Xanthomonas mango, strawberry angular leaf spot caused by Xanthomonas fragaria, etc. These pathogens have become difficulties and obstacles in agricultural production around the world due to their rapid reproduction, strong transmission ability, and easy development of drug resistance. Pesticides are the key to controlling these diseases. At present, chemically synthesized antimicrobial agents are mainly used to reduce and control the degree of harm of these diseases, but long-term irrational use has not only led to the development of drug resistance in pathogens, but also had a negative impact on human health and the environment. A sustainable strategy to combat these diseases is to find new antimicrobial agents with low toxicity, good environmental compatibility and unique mechanisms of action for alternating use.

[0003] Green plant-based pesticides have the advantages of high efficiency, low toxicity, high selectivity, and pests and diseases are not easy to develop resistance. Today, as environmental protection is increasingly valued, they have attracted widespread attention from the world's pesticide industry, which provides development opportunities and huge market space for the development of green plant-based pesticides. Therefore, finding antibacterial active ingredients from plants and modifying and transforming them to become effective mothers of innovative pesticides is an important way to create green plant-based pesticides.

[0004] Formononetin (FMN, 7-hydroxy-4'-methoxy isoflavone) is a member of the isoflavone family and is widely found in leguminous plants such as Astragalus, Licorice, Pueraria, and Tripterygium wilfordii. Modern pharmacological studies have shown that formononetin not only has antibacterial, anti-tumor, anti-lipid, anti-arrhythmic, and anti-lipid peroxidation effects, but also can improve atherosclerosis, scavenge oxygen free radicals, and inhibit the proliferation of vascular smooth muscle cells. In 2008, Yang et al. synthesized 17 new formononetin derivatives and screened the antibacterial activity of the synthesized compounds. The results showed that some compounds had good antibacterial activity against Bacillus subtilis, with a minimum inhibitory concentration (MIC) of 0.78 μg / mL. In 2016, Zhang et al. reported a structural modification of formononetin that had a good inhibitory effect on Helicobacter pylori and had a high clinical application value, providing a new choice for the treatment of Helicobacter pylori. In 2019, Yang et al. reported a series of formononetin derivatives with anti-breast cancer effects. The experimental results showed that the synthesized compounds had inhibitory activity against breast cancer cells SUM159 and MCF-7, with the optimal IC50 of 0.36μM, and can be used to treat breast cancer. In 2020, Besbas et al. extracted a formononetin glycoside from Solanum nigrum and studied its biological activity. The results showed that the analogue had good antioxidant, anti-hemolytic and anti-inflammatory activities. A large number of literature surveys have found that research on formononetin and its derivatives mainly focuses on the medical field, and has significant clinical efficacy, but there are few applications and reports on formononetin and its derivatives in the field of pesticides.

[0005] Piperidine is a nitrogen-containing heterocyclic ring commonly found in natural alkaloids. It not only has a broad spectrum of biological activities such as antibacterial, antiviral, anticancer, and antioxidant, but also has the advantages of good selectivity, high activity, and low toxicity. For example, piperine, a broad-spectrum anticonvulsant, febrifugin, an antimalarial active ingredient, rapamycin, an immunosuppressant, and cycloheximide, an antibiotic. In the field of medicine and pesticides, piperidine is an important pharmacophore, and its derivatives have a wide range of pharmacological activities such as antibacterial, anti-inflammatory, antiviral, anticancer, antimalarial, and antipsychotic, which makes piperidine a favored dominant skeleton in drug synthesis. Molecular building blocks containing piperidine are also frequently used in the synthesis of small drug molecules. Benzylpiperidine is an important intermediate compound commonly used in organic synthesis. It can be used as a catalyst, ligand, or raw material to participate in different types of chemical reactions, such as carbonylation, diazotization, and Michael addition.

[0006] In summary, there is no report on the introduction of benzylpiperidine into the structure of formononetin to synthesize formononetin derivatives containing benzylpiperidine, and there is no report on the use of formononetin derivatives containing benzylpiperidine for agricultural activity research. Summary of the invention

[0007] The object of the present invention is to provide a formononetin derivative containing benzylpiperidine and a preparation method and application thereof. The provided formononetin derivative containing benzylpiperidine can be used to inhibit plant pathogenic bacteria, especially Xanthomonas.

[0008] To achieve the above object, the present invention provides the following technical solutions:

[0009] One of the technical solutions of the present invention is to provide a formononetin derivative containing benzylpiperidine, the structure of which is shown in the following formula:

[0010]

[0011] In the above formula, n is an integer from 2 to 6, and R is independently selected from H, one or more halogens, one or more nitro groups, one or more C1-C6 alkyl groups, one or more C1-C6 substituted alkyl groups, one or more C1-C6 alkoxy groups, or one or more C1-C6 substituted alkoxy groups.

[0012] Preferably, the halogen is F, Cl or Br.

[0013] The second technical solution of the present invention is to provide a method for preparing the formononetin derivative containing benzylpiperidine, the steps comprising:

[0014] (1) Using formononetin and dibromoalkane as raw materials, heating in a solvent under alkaline conditions for reaction, adding ice water after the reaction is completed to precipitate the product, filtering, and removing impurities from the filter residue to obtain intermediate a;

[0015] The structural formula of the dibromoalkane is: Wherein, n is an integer from 2 to 6;

[0016] The structural formula of the intermediate a is: Wherein, n is an integer from 2 to 6;

[0017] (2) using intermediate a and 1-boc-4-methylaminopiperidine as raw materials and potassium carbonate as a catalyst, heating the reaction in a solvent to obtain intermediate b;

[0018] The structural formula of the intermediate b is: Wherein, n is an integer from 2 to 6;

[0019] (3) Using intermediate b as raw material, removing the boc protection, intermediate c is obtained;

[0020] The structural formula of the intermediate c is: Wherein, n is an integer from 2 to 6;

[0021] (4) using intermediate c and substituted benzyl chloride as raw materials and potassium carbonate as a catalyst, heating under reflux to obtain the formononetin derivative containing benzylpiperidine;

[0022] The structural formula of the substituted benzyl chloride is: Wherein, R is independently selected from H, one or more halogens, one or more nitro groups, one or more C1-C6 alkyl groups, one or more C1-C6 substituted alkyl groups, one or more C1-C6 alkoxy groups, or one or more C1-C6 substituted alkoxy groups.

[0023] Preferably, the molar ratio of formononetin to dibromoalkane in step (1) is 11.0:(54.8-109.6); the temperature of the heating reaction is 80°C and the time is 4-10 hours; the alkaline condition is provided by anhydrous potassium carbonate; the impurity removal step comprises: washing the filter residue with water and petroleum ether in sequence, then pulping, standing, filtering, and completing washing.

[0024] More preferably, in step (1), the molar ratio of formononetin to anhydrous potassium carbonate is 11.0:32.9; and the solution used for pulping is a mixture of petroleum ether and ethyl acetate in a volume ratio of 3:1.

[0025] Preferably, in step (2), the molar ratio of the intermediate a, 1-boc-4-methylaminopiperidine and potassium carbonate is 3.9:(3.9-7.7):(11.6-38.5); the temperature of the heating reaction is 80° C. and the time is 4-10 hours; and a purification step is also included after the heating reaction.

[0026] More preferably, the purification step specifically comprises: filtering the reaction system after the heating reaction, evaporating the filtrate to dryness, and performing column chromatography to complete purification; wherein the eluent used for the column chromatography is ethyl acetate.

[0027] Preferably, the step of removing the boc protection in step (3) comprises: dissolving the intermediate b in methanol, heating to 40-80° C., adding dropwise a 15-37% HCl solution, reacting for 1-4 hours, and removing the boc protection.

[0028] Preferably, the step (3) further comprises a separation step after the removal of the boc protection, wherein the separation step is specifically as follows: after the removal of the boc protection, the reaction system is poured into ice water, the system is adjusted to 8-9 using a 5wt% NaHCO3 solution, and then extracted with dichloromethane, and the extract is evaporated to dryness to obtain intermediate b.

[0029] Preferably, in step (4), the molar ratio of the intermediate c, substituted benzyl chloride and potassium carbonate is 1.2:(1.2-1.4):(2.4-3.6); and the heating reflux time is 1-2 h.

[0030] Preferably, the step (4) further comprises a purification step after the heating and reflux, and the purification step specifically comprises: pouring the reaction system after the heating and reflux into water, extracting with dichloromethane, evaporating the extract to dryness, and performing column chromatography to complete purification; wherein the eluent used for the column chromatography is a mixture of dichloromethane and methanol in a volume ratio of 40:1.

[0031] The third technical solution of the present invention is to provide an application of the above-mentioned formononetin derivative containing benzylpiperidine in the preparation of drugs for inhibiting plant pathogenic bacteria.

[0032] Preferably, the plant pathogenic bacteria include one or more of Xanthomonas oryzae, Xoo; Xanthomonas citri citri odoratus, Xac; Xcm; Xanthomonas oxysporum, Xf.; Psa. oxysporum, Pcb; Ac. melanocarpa; and Ps. solanacearum.

[0033] The beneficial technical effects of the present invention are as follows:

[0034] The invention provides a formononetin derivative containing benzylpiperidine, and a preparation method and application thereof. The invention introduces a benzylpiperidine group with excellent activity into the structure of formononetin, and synthesizes a series of formononetin derivatives containing benzylpiperidine. By testing the inhibitory activity of the synthesized formononetin derivatives containing benzylpiperidine on plant pathogenic bacteria, it is found that the synthesized formononetin derivatives containing benzylpiperidine can effectively inhibit plant pathogenic bacteria, especially Xanthomonas. DETAILED DESCRIPTION

[0035] Now, various exemplary embodiments of the present invention are described in detail, and this detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, characteristics and embodiments of the present invention. It should be understood that the terms described in the present invention are only for describing specific embodiments and are not used to limit the present invention.

[0036] In addition, for the numerical range in the present invention, it is understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0037] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the invention pertains. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention.

[0038] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0039] One of the technical objectives of the present invention is to provide a formononetin derivative containing benzylpiperidine, the structure of which is shown in the following formula:

[0040]

[0041] In the above formula, n is an integer from 2 to 6, and R is independently selected from H, one or more halogens, one or more nitro groups, one or more C1-C6 alkyl groups, one or more C1-C6 substituted alkyl groups, one or more C1-C6 alkoxy groups, or one or more C1-C6 substituted alkoxy groups.

[0042] Preferably, the halogen is F, Cl or Br.

[0043] The second technical purpose of the present invention is to provide a method for preparing the formononetin derivative containing benzylpiperidine, the steps comprising:

[0044] (1) Using formononetin and dibromoalkane as raw materials, heating the reaction at 80°C in an alkaline solvent for 4 to 10 hours. After the reaction is completed, the reaction system is dispersed with ice water, and then filtered, washed, and slurried to obtain intermediate a;

[0045] The reaction formula is as follows:

[0046]

[0047] In some embodiments, the solvent is ethanol; after the reaction is completed, the reaction solution is dispersed with ice water to precipitate solids; after the solids are precipitated, filtration and washing steps are also included; the washing is washing with water and petroleum ether respectively; the pulping is pulping with petroleum ether / ethyl acetate = 3:1 (v / v);

[0048] Wherein, the molar ratio of the formononetin to dibromoalkane is 11.0:(54.8-109.6); the molar ratio of the formononetin to anhydrous potassium carbonate is 11.0:32.9;

[0049] (2) Using intermediate a and 1-boc-4-methylaminopiperidine as raw materials and potassium carbonate as a catalyst, the reaction was carried out in acetonitrile solvent at 80° C. for 8 to 10 hours to prepare intermediate b;

[0050] The reaction formula is as follows:

[0051]

[0052] In some embodiments, after the reaction is completed, the steps further include filtration, vacuum rotary evaporation, and column chromatography; the filtration is to remove insoluble substances; the column chromatography uses pure ethyl acetate as an eluent;

[0053] Wherein, the molar ratio of the intermediate a, 1-boc-4-methylaminopiperidine and potassium carbonate is 3.9:(3.9-7.7):(11.6-38.5);

[0054] (3) Using intermediate b as raw material and methanol as solvent, add 15-37 wt.% HCl solution dropwise at 40-80°C to react for 1-4h to remove the boc protection, then pour the reaction system into ice water, and adjust the system to alkalinity with NaHCO3 aqueous solution to prepare intermediate c;

[0055] The reaction formula is as follows:

[0056]

[0057] In some embodiments, the concentration of the NaHCO3 aqueous solution is 5wt.%; the alkaline pH value is 8-9; after adjusting to alkalinity, extraction and reduced pressure rotary evaporation are also included; the extraction is performed using dichloromethane;

[0058] (4) using intermediate c and substituted benzyl chloride as raw materials and potassium carbonate as a catalyst, refluxing in a solvent to prepare a formononetin derivative containing benzylpiperidine;

[0059] The reaction formula is as follows:

[0060]

[0061] In some embodiments, the solvent is acetonitrile; the reflux reaction time is 1 to 2 hours; after the reaction is completed, the reaction system is dispersed in water, followed by extraction, drying, vacuum rotary evaporation, and column chromatography, and the column chromatography eluent is a mixture of dichloromethane and methanol in a volume ratio of 40:1.

[0062] Wherein, the molar ratio of the intermediate c, substituted benzyl chloride and potassium carbonate is 1.2:(1.2-1.4):(2.4-3.6).

[0063] The third technical purpose of the present invention is to provide an application of the above-mentioned formononetin derivative containing benzylpiperidine in the preparation of drugs for inhibiting plant pathogenic bacteria.

[0064] To achieve the above technical objectives, the present invention provides the following embodiments.

[0065] Example 1

[0066] 7-(3-((1-benzylpiperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H1), the steps are as follows:

[0067] (1) Synthesis of 7-(3-bromopropoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one: In a 250 mL three-necked flask, formononetin (3.0 g, 11.0 mmol), anhydrous potassium carbonate (4.5 g, 32.9 mmol), and 80 mL of ethanol were added and the temperature was raised to 80°C and stirred for 0.5 h. Then, dibromopropane (5.6 mL, 54.8 mmol) was slowly added and reacted for 6 h. After the reaction was completed, it was dispersed with 500 mL of ice water to precipitate a large amount of solid. The solid was filtered, washed with water and petroleum ether for several times, dried, and the obtained white solid was slurried with 60 mL of a solvent of petroleum ether / ethyl acetate = 3:1, v / v, overnight. The solid was filtered to obtain a white solid with a yield of 85.6%.

[0068] (2) Synthesis of tert-butyl-4-((3-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)propyl)(methyl)amino)piperidine-1-carboxylate: 1-boc-4-methylaminopiperidine (1.65 g, 7.71 mmol) and anhydrous K2CO3 (5.33 g, 38.54 mmol) were added to 250 mL of acetonitrile solution, stirred at room temperature for 0.5 h, and then 7-(3-bromopropoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (1.5 g, 3.85 mmol) was added to the system. The temperature was raised to 80°C and the reaction was carried out for 8 h. After the reaction was completed, the mixture was filtered, the filter cake was washed with dichloromethane, the filtrate was collected and evaporated under reduced pressure, and then purified by column chromatography using pure ethyl acetate to obtain a white solid with a yield of 64.3%.

[0069] (3) Preparation of 3-(4-methoxyphenyl)-7-(3-(methyl(piperidin-4-yl)amino)propoxy)-4H-chromen-4-one: The product in step (2) was dissolved in 50 mL of methanol in a 100 mL single-necked flask, and 6 mL of 15 wt.% aqueous hydrochloric acid solution was added dropwise, and refluxed at 60° C. for 2 h. After the reaction was completed, a large amount of solvent was removed by vacuum evaporation, and the system was dispersed in 100 mL of water, and the pH value was adjusted to 8-9 with 5 wt.% NaHCO3 solution, extracted with dichloromethane, and the organic phase was collected. The solvent was removed by vacuum evaporation to obtain an oily substance with a yield of 87.3%.

[0070] (4) Synthesis of 7-(3-((1-benzylpiperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one: 3-(4-methoxyphenyl)-7-(3-(methyl(piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (0.5 g, 1.18 mmol), anhydrous K2CO3 (0.33 g, 2.37 mmol), 20 m 1 L acetonitrile was added into a 50 mL round-bottom flask. After heating and reflux with stirring for 0.5 h, benzyl chloride (170 μL, 1.42 mmol) was slowly added dropwise and reacted for 2 h. After the reaction was completed, the system was dispersed into 100 mL of water and extracted with dichloromethane for 3 times. The organic phase was collected and dried over anhydrous Na2SO4. The crude product was obtained by rotary evaporation under reduced pressure. The target compound was obtained by column chromatography (dichloromethane: methanol = 40: 1, v / v) with a yield of 57%.

[0071] Example 2

[0072] Synthesis of 7-(3-((1-(4-chlorobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H2), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 4-chlorobenzyl chloride. Yield: 44%.

[0073] Example 3

[0074] The synthesis of 7-(3-((1-(3-chlorobenzyl)piperidin-4-yl)(methyl 1)amino)propoxy-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H3) was carried out in the same manner as in Example 1, except that the benzyl chloride in step (4) was replaced by an equimolar amount of 3-chlorobenzyl chloride. Yield: 43%.

[0075] Example 4

[0076] Synthesis of 7-(3-((1-(2-chlorobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H4), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 2-chlorobenzyl chloride. Yield: 58%.

[0077] Example 5

[0078] Synthesis of 7-(3-((1-(4-fluorobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H5), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equimolar amount of 4-fluorobenzyl chloride. Yield: 50%.

[0079] Example 6

[0080] Synthesis of 7-(3-((1-(3-fluorobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H6), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equimolar amount of 3-fluorobenzyl chloride. Yield: 66%.

[0081] Example 7

[0082] Synthesis of 7-(3-((1-(2-fluorobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H7), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 2-fluorobenzyl chloride. Yield: 51%

[0083] Example 8

[0084] Synthesis of 7-(3-((1-(4-bromobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H8), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equimolar amount of 4-bromobenzyl chloride. Yield: 47%.

[0085] Example 9

[0086] Synthesis of 7-(3-((1-(2-bromobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H9), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 2-bromobenzyl chloride. Yield: 60%.

[0087] Example 10

[0088] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(4-methylbenzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (Compound No. H10), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 4-methylbenzyl chloride. Yield: 54%.

[0089] Embodiment 11

[0090] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(3-methylbenzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (compound number H11), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 3-methylbenzyl chloride. Yield: 50%.

[0091] Example 12

[0092] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(2-methylbenzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (compound number H12), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 2-methylbenzyl chloride. Yield: 54%.

[0093] Embodiment 13

[0094] Synthesis of 7-(3-((1-(4-methoxybenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H13), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 4-methoxybenzyl chloride. Yield: 48%.

[0095] Embodiment 14

[0096] Synthesis of 7-(3-((1-(3-methoxybenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H14), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 3-methoxybenzyl chloride. Yield: 58%.

[0097] Embodiment 15

[0098] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(4-nitrobenzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (compound number H15), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 4-nitrobenzyl chloride. Yield: 75%.

[0099] Example 16

[0100] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(3-nitrobenzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (compound number H16), the steps are the same as those in Example 1, except that the benzyl chloride in step (5) is replaced by an equal molar amount of 3-nitrobenzyl chloride. Yield: 62%.

[0101] Embodiment 17

[0102] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (Compound No. H17), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 4-trifluoromethylbenzyl chloride. Yield: 58%.

[0103] Embodiment 18

[0104] Synthesis of 3-(4-methoxyphenyl)-7-(3-(methyl(1-(3-(trifluoromethyl)benzyl)piperidin-4-yl)amino)propoxy)-4H-chromen-4-one (compound number H18), the steps are the same as those in Example 1, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 3-nitrobenzyl chloride. Yield: 32%.

[0105] Embodiment 19

[0106] The synthesis of 7-(3-((1-(2,4-dichlorobenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H19) was carried out in the same manner as in Example 1, except that the benzyl chloride in step (4) was replaced with an equal molar amount of 2,4-dichlorobenzyl chloride. Yield: 58%.

[0107] Embodiment 20

[0108] Synthesis of 7-(3-((1-(3,4-dimethylbenzyl)piperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H20), the steps are the same as those in Example 1, except that the benzyl chloride in step (5) is replaced by an equal molar amount of 3,4-dimethylbenzyl chloride. Yield: 38%.

[0109] Embodiment 21

[0110] The synthesis of 7-(4-((1-benzylpiperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H21) is as follows:

[0111] (1) Synthesis of 7-(4-bromobutoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one: The same as step 1 of Example 1, except that 1,3-dibromopropane is replaced with an equal molar amount of 1,4-dibromobutane.

[0112] (2) Synthesis of tert-butyl 4-((4-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)butyl)(methyl)amino)piperidine-1-carboxylate: The same as step 2 of Example 1, except that 7-(3-bromopropoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one was replaced with an equal molar amount of 7-(4-bromobutoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one.

[0113] (3) Preparation of 3-(4-methoxyphenyl)-7-(4-(methyl(piperidin-4-yl)amino)butoxy)-4H-chromen-4-one: The same as step 3 of Example 1, except that tert-butyl-4-((3-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)propyl)(methyl)amino)piperidine-1-carboxylate is replaced with an equal molar amount of tert-butyl 4-((4-((3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl)oxy)butyl)(methyl)amino)piperidine-1-carboxylate.

[0114] (4) Synthesis of 7-(4-((1-benzylpiperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one: 7-(4-((1-benzylpiperidin-4-yl)(methyl)amino)propoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (0.5 g, 1.5 mmol) and anhydrous K2CO3 (0.32 g, 2.29 mmol) were added to 20 mL acetonitrile solution was added into a 50 mL round-bottom flask. After heating and reflux with stirring for 30 min, benzyl chloride (165 μL, 1.37 mmol) was slowly added dropwise and reacted for 2 h. After the reaction was completed, the system was dispersed into 100 mL of water and extracted with dichloromethane three times. The organic phase was collected and dried over anhydrous Na2SO4. The crude product was obtained by rotary evaporation under reduced pressure. The target compound was obtained by column chromatography (dichloromethane: methanol = 40: 1, v / v) with a yield of 45%.

[0115] Embodiment 22

[0116] Synthesis of 7-(4-((1-(4-chlorobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H22) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 4-chlorobenzyl chloride. Yield: 68%.

[0117] Embodiment 23

[0118] Synthesis of 7-(4-((1-(3-chlorobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H23) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 3-chlorobenzyl chloride. Yield: 41%.

[0119] Embodiment 24

[0120] Synthesis of 7-(4-((1-(2-chlorobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H24) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 2-chlorobenzyl chloride. Yield: 44%.

[0121] Embodiment 25

[0122] Synthesis of 7-(4-((1-(4-fluorobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H25) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 4-fluorobenzyl chloride. Yield: 61%.

[0123] Embodiment 26

[0124] Synthesis of 7-(4-((1-(3-fluorobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H26) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 3-fluorobenzyl chloride. Yield: 77%.

[0125] Embodiment 27

[0126] Synthesis of 7-(4-((1-(2-fluorobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H27) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 2-fluorobenzyl chloride. Yield: 38%.

[0127] Embodiment 28

[0128] Synthesis of 7-(4-((1-(4-bromobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H28) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equimolar amount of 4-bromobenzyl chloride. Yield: 41%.

[0129] Embodiment 29

[0130] Synthesis of 7-(4-((1-(3-bromobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H29) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 3-bromobenzyl chloride. Yield: 43%.

[0131] Embodiment 30

[0132] Synthesis of 3-(4-methoxyphenyl)-7-(4-(methyl(1-(4-methylbenzyl)piperidin-4-yl)amino)butoxy)-4H-chromen-4-one (Compound No. H30) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 4-methylbenzyl chloride. Yield: 58%.

[0133] Embodiment 31

[0134] Synthesis of 3-(4-methoxyphenyl)-7-(4-(methyl(1-(3-methylbenzyl)piperidin-4-yl)amino)butoxy)-4H-chromen-4-one (Compound No. H31), the steps are the same as those of Example 21, except that the benzyl chloride in step (4) is replaced by an equal molar amount of 3-methylbenzyl chloride. Yield: 56%.

[0135] Embodiment 32

[0136] Synthesis of 3-(4-methoxyphenyl)-7-(4-(methyl(1-(3-methylbenzyl)piperidin-4-yl)amino)butoxy)-4H-chromen-4-one (Compound No. H32) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 2-methylbenzyl chloride. Yield: 57%.

[0137] Embodiment 33

[0138] Synthesis of 7-(4-((1-(4-methoxybenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H33) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 4-methoxybenzyl chloride. Yield: 62%.

[0139] Embodiment 34

[0140] Synthesis of 7-(4-((1-(3-methoxybenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H34) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 3-methoxybenzyl chloride. Yield: 53%.

[0141] Embodiment 35

[0142] Synthesis of 7-(4-((1-(4-nitrobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H35) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 4-nitrobenzyl chloride. Yield: 32%.

[0143] Embodiment 36

[0144] Synthesis of 7-(4-((1-(3-nitrobenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H36) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 3-nitrobenzyl chloride. Yield: 47%.

[0145] Embodiment 37

[0146] Synthesis of 7-(4-((1-(4-trifluoromethylbenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H37) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 4-trifluoromethylbenzyl chloride. Yield: 63%.

[0147] Embodiment 38

[0148] Synthesis of 7-(4-((1-(3-trifluoromethylbenzyl)piperidin-4-yl)(methyl)amino)butoxy)-3-(4-methoxyphenyl)-4H-chromen-4-one (Compound No. H38) was carried out in the same manner as in Example 21, except that benzyl chloride in step (4) was replaced with an equal molar amount of 3-trifluoromethylbenzyl chloride. Yield: 42%.

[0149] Embodiment 39

[0150] The synthesis of 7-(4-((1-(2,4-dichlorobenzyl)piperidin-4-yl)(methyl)amino)butoxy-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H39) was carried out in the same manner as in Example 21, except that the benzyl chloride in step (4) was replaced with an equimolar amount of 2,4-dichlorobenzyl chloride. Yield: 42%.

[0151] Embodiment 40

[0152] The synthesis of 7-(4-((1-(3,4-dimethylbenzyl)piperidin-4-yl)(methyl)amino)butoxy-3-(4-methoxyphenyl)-4H-chromen-4-one (compound number H40) was carried out in the same manner as in Example 21, except that the benzyl chloride in step (4) was replaced by an equal molar amount of 3,4-dimethylbenzyl chloride. Yield: 53%.

[0153] The physicochemical properties and mass spectrometry data of the formononetin derivatives containing benzylpiperidine synthesized in Examples 1 to 40 are shown in Table 1. The H NMR spectrum ( 1 H NMR) and carbon spectroscopy ( 13 C NMR) data are shown in Table 2.

[0154] Table 1 Physicochemical properties of target compounds and their mass spectrometry analysis data

[0155] Compound Yield (%) Characteristics Melting point(℃) HRMS, m / z (calcd.) H1 57% White solid 73-74 <![CDATA[513.27478(513.27441)[M+H] + ]]> H2 44% White solid 70-71 <![CDATA[547.23581(547.23529)[M+H] + ]]> H3 43% White solid 91-92 <![CDATA[547.23581(547.23529)[M+H] + ]]> H4 58% White solid 74-75 <![CDATA[547.23581(547.23535)[M+H] + ]]> H5 50% White solid 99-100 <![CDATA[531.26536(531.26477)[M+H] + ]]> H6 66% White solid 67-69 <![CDATA[531.26536(531.26489)[M+H] + ]]> H7 51% White solid 63-64 <![CDATA[531.26536(531.26489)[M+H] + ]]> H8 47% White solid 67-68 <![CDATA[591.18530(591.18481)[M+H] + ]]> H9 60% White solid 89-91 <![CDATA[591.18530(591.18475)[M+H] + ]]> H10 54% White solid 66-67 <![CDATA[527.29043(527.29010)[M+H] + ]]> H11 50% White solid 91-93 <![CDATA[527.29043(527.28992)[M+H] + ]]> H12 54% White solid 74-76 <![CDATA[527.29043(527.29010)[M+H] + ]]> H13 48% White solid 68-69 <![CDATA[543.28535(543.28497)[M+H] + ]]> H14 58% White solid 64-65 <![CDATA[543.28535(543.28491)[M+H] + ]]> H15 75% White solid 62-63 <![CDATA[558.25986(558.25958)[M+H] + ]]> H16 62% White solid 77-79 <![CDATA[558.25986(558.25958)[M+H] + ]]> H17 58% White solid 69-71 <![CDATA[581.26217(581.26178)[M+H] + ]]> H18 32% White solid 70-71 <![CDATA[581.26217(581.26172)[M+H] + ]]> H19 58% White solid 64-65 <![CDATA[581.19684(581.19635)[M+H] + ]]> H20 38% White solid 50-51 <![CDATA[541.30608(541.30591)[M+H] + <!-- 11 -->]]> H21 45% White solid 84-85 527.29043(527.28992)[M+H]+ H22 68% White solid 95-96 561.25146(561.25098)[M+H]+ H23 41% White solid 84-85 561.25146(561.25098)[M+H]+ H24 44% White solid 98-99 561.25146(561.25073)[M+H]+ H25 61% White solid 83-84 545.28101(545.28052)[M+H]+ H26 77% White solid 75-76 545.28101(545.28052)[M+H]+ H27 38% White solid 89-90 545.28101(545.28058)[M+H]+ H28 41% White solid 109-110 605.20095(605.20038)[M+H]+ H29 43% White solid 77-78 605.20095(605.20032)[M+H]+ H30 58% White solid 95-96 541.30608(541.30646)[M+H]+ H31 56% White solid 92-94 541.30608(541.30566)[M+H]+ H32 57% White solid 82-84 541.30608(541.30573)[M+H]+ H33 62% White solid 87-88 557.30100(557.30011)[M+H]+ H34 53% White solid 71-72 557.30100(557.30060)[M+H]+ H35 32% White solid 97-99 572.27551(572.27490)[M+H]+ H36 47% White solid 80-82 572.27551(572.27502)[M+H]+ H37 63% White solid 86-88 595.27782(595.27728)[M+H]+ H38 42% White solid 80-82 595.27782(595.27728)[M+H]+ H39 43% White solid 109-111 595.21249(595.21179)[M+H]+ H40 51% White solid 101-103 555.32173(555.32141)[M+H]+

[0156] Table 2 NMR spectrum data of target compounds

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163] Test Example 1

[0164] Anti-plant pathogenic bacteria activity test

[0165] Test method:

[0166] The in vitro activity of four Xanthomonas species (Xoo, Xanthomonas oryzae; Xac, Xcm, Xf., Xanthomonas oxysporum) and four non-Xanthomonas species (Psa, Psa, Pcb, Ac, Ps. melon fruit spot; Ps. solanacearum) was evaluated by turbidity method, and commercial agents Thiabendazole and Zinc Thiazole were used as positive controls. The specific steps are as follows:

[0167] (1) The above eight plant pathogenic bacteria were evenly spread on NA solid culture medium and cultured in a constant temperature bacterial incubator at 28°C until single colonies grew. An appropriate number of central single colonies were selected and placed in NB liquid culture medium and cultured in a constant temperature shaker at 28°C and 180 r / min until the logarithmic growth phase (OD 595 =0.6-0.8).

[0168] (2) Prepare 5 mL of 100 μg / mL drug-containing NB culture medium in a test tube for the sample and control agent, and add 1% DMSO to the test tube for the control group. Take 200 μL from each test tube and measure its OD value, which is the OD value of the sterile culture medium. 595 Then, 40 μL of the tested bacteria were inoculated into each test tube and cultured in a constant temperature shaker at 28°C and 180 r / min for 12-48 hours. When the turbidity value was between 0.6 and 0.8, the OD of each test tube was measured. 595 The inhibition rate of the tested compounds was calculated according to the following formula, and the results are shown in Table 3.

[0169] (3) Correction OD 595 Value = OD of culture medium containing bacteria 595 Value - sterile culture medium OD 595 value

[0170] Inhibition rate (%) = (corrected control culture medium bacterial solution OD 595 - Correction of OD of drug-containing culture medium 595 ) / corrected OD value of bacterial solution in control culture medium × 100%.

[0171] (4) The results of the biological activity test against plant pathogenic fungi are shown in Table 3.

[0172] Table 3 In vitro antibacterial activity of H1-H40 (100 μg / mL)

[0173]

[0174]

[0175] As can be seen from Table 3, all target compounds have certain inhibitory activity against 8 plant bacteria at a concentration of 100 μg / mL. Among them, the inhibition rates of H1-H8, H10-H21, H23-H27, H29-H34, H36, H38 and H40 against Xoo are all 100%, which is better than thiophanate-methyl (74.2%) and thiazole zinc (90.8%). The inhibitory activity of compounds H1-H2, H5-H8, H10, H13-H21, H25-H26 and H33-H34 against Xac is 100%, which is significantly better than thiophanate-methyl (50.4%) and thiazole zinc (68.6%). Compounds H1-H2, H5-H8, H10, H13-H15, H17, H19-H21 and H33-H34 showed the most significant inhibitory effect on Xcm, with an inhibition rate of 100%, significantly better than thiophanate-methyl (72.9%) and zinc thiazole (91.8%). Compounds H1-H2, H6-H8, H10, H13-H15, H17-H18, H20-H21, H26, H31, H33-H34 and H40 showed 100% inhibitory activity on Xf, exceeding thiophanate-methyl (84.5%) and zinc thiazole (59.6%). In addition, some compounds also had good antibacterial activity against four non-Xanthomonas bacteria (Psa, Pcb, Ac, Rs). In general, the inhibitory activity of the target compounds against four Xanthomonas species (Xoo, Xac, Xcm, Xf) was significantly better than that against four non-Xanthomonas species (Psa, Pcb, Ac, Rs. Therefore, the target compounds have specific inhibitory activity against Xanthomonas.

[0176] The above experimental activity data show that the benzylpiperidine-containing formononetin derivatives have a good inhibitory effect on plant pathogenic bacteria, especially Xanthomonas, and can be used as potential anti-plant pathogenic bacteria drugs with good application prospects.

[0177] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A formononetin derivative containing benzylpiperidine, characterized in that: The structure is shown below: In the above formula, n is an integer from 2 to 6, and R is independently selected from H, one or more halogens, one or more nitro groups, one or more C1-C6 alkyl groups, one or more C1-C6 substituted alkyl groups, one or more C1-C6 alkoxy groups, or one or more C1-C6 substituted alkoxy groups.

2. A method for preparing the formononetin derivative containing benzylpiperidine according to claim 1, characterized in that the steps include: (1) Using formononetin and dibromoalkane as raw materials, heating in a solvent under alkaline conditions for reaction, adding ice water after the reaction is completed to precipitate the product, filtering, and removing impurities from the filter residue to obtain intermediate a; The structural formula of the dibromoalkane is: Wherein, n is an integer from 2 to 6; The structural formula of the intermediate a is: Wherein, n is an integer from 2 to 6; (2) using intermediate a and 1-boc-4-methylaminopiperidine as raw materials and potassium carbonate as a catalyst, heating the reaction in a solvent to obtain intermediate b; The structural formula of the intermediate b is: Wherein, n is an integer from 2 to 6; (3) Using intermediate b as raw material, removing the boc protection, intermediate c is obtained; The structural formula of the intermediate c is: Wherein, n is an integer from 2 to 6; (4) using intermediate c and substituted benzyl chloride as raw materials and potassium carbonate as a catalyst, heating under reflux to obtain the formononetin derivative containing benzylpiperidine; The structural formula of the substituted benzyl chloride is: Wherein, R is independently selected from H, one or more halogens, one or more nitro groups, one or more C1-C6 alkyl groups, one or more C1-C6 substituted alkyl groups, one or more C1-C6 alkoxy groups, or one or more C1-C6 substituted alkoxy groups.

3. The preparation method according to claim 2, characterized in that: The molar ratio of formononetin to dibromoalkane in step (1) is 11.0:(54.8-109.6); the temperature of the heating reaction is 80°C and the time is 4-10 hours; the alkaline condition is provided by anhydrous potassium carbonate; the impurity removal step comprises: washing the filter residue with water and petroleum ether in sequence, then pulping, standing, filtering, and completing washing.

4. The preparation method according to claim 3, characterized in that: The molar ratio of formononetin to anhydrous potassium carbonate in step (1) is 11.0:32.9; the solution used for pulping is a mixture of petroleum ether and ethyl acetate in a volume ratio of 3:

1.

5. The preparation method according to claim 2, characterized in that: The molar ratio of the intermediate a, 1-boc-4-methylaminopiperidine and potassium carbonate in step (2) is 3.9:(3.9-7.7):(11.6-38.5); the temperature of the heating reaction is 80° C. and the time is 4-10 hours; and a purification step is also included after the heating reaction.

6. The preparation method according to claim 2, characterized in that: The step of removing the boc protection in step (3) comprises: dissolving the intermediate b in methanol, heating to 40-80° C., adding dropwise a 15-37% HCl solution, reacting for 1-4 hours, and removing the boc protection.

7. The preparation method according to claim 2, characterized in that: After removing the boc protection in step (3), a separation step is further included. The separation step is specifically as follows: after removing the boc protection, the reaction system is poured into ice water, the system is adjusted to 8-9 using a 5wt% NaHCO3 solution, and then extracted with dichloromethane, and the extract is evaporated to dryness to obtain intermediate b.

8. The preparation method according to claim 2, characterized in that: In step (4), the molar ratio of the intermediate c, substituted benzyl chloride and potassium carbonate is 1.2:(1.2-1.4):(2.4-3.6); the heating reflux time is 1-2h.

9. Use of the formononetin derivative containing benzylpiperidine according to claim 1 in the preparation of a drug for inhibiting plant pathogenic bacteria.

10. The use according to claim 9, characterized in that: The plant pathogenic bacteria include one or more of X. oryzae, Xoo; X. citrus canker, Xac; Xcm. mango bacterial angular spot pathogen; Xf. strawberry angular spot pathogen; Psa. kiwifruit canker pathogen; Pcb. potato soft rot pathogen; Ac. melon fruit spot pathogen; and Ps. tomato bacterial wilt pathogen.

Citation Information

Patent Citations

  • Preparation method and applications of isoflavone type compounds with selective estrogen receptor modulating activity

    CN102161648A

  • Genistein alkylamine compound, preparation method and use of genistein alkylamine compound

    CN103113340A

  • Preparation method of genistein derivative containing benzylpiperazine and application of genistein derivative for protecting gastric mucosal

    CN104292199A

  • Application of natural source flavonoid compounds as antibacterial agents in inhibition of plant pathogenic bacteria

    CN113455507A